Skip to main content

Fiscal Wizard · Single-issue tearsheet

PLUR / Jun 22, 2026 Run #7699

PLUR

Pluri Inc.

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Composite verdict

F 14.0 / 100
Bearish setup · Trend Following 14 drivers · 6 gates blocking
  • Rate of Change
  • Vortex Signal
  • 52-Week Proximity
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 378th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 50
  • Late-stage trendTrend signals have been live for 64 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

28.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Return on Capital Employed 0
Revenue Growth (YoY) 100
Free Cash Flow Yield 0
Greenblatt EY 7

Technicals Bearish

0.0 / 100

Bearish setup leads (Rate of Change, Vortex Signal, 52-Week Proximity); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 6
52-Week Proximity 9
Vortex Signal 11

Risk Gates

6 blocking 4 caution

6 guards active, 18 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for PLUR.